MedElevator Войти в исследования
← Поиск публикаций

DOI 10.7759/cureus.57842

Медицинская библиотека · Cureus · 2024

Cardiovascular Morbidity in Systemic Lupus Erythematosus: A Single-Center Retrospective Study.

Alammari Yousef, Albednah Fahed A, Alharbi Khalid A, Alrashoudi Abdulrahman M, Alsharif Abdulaziz Y, Alkahtani Abdullah H, Alshehry Hasan Z, Alajaji Abdulrahman A, Alsaedi Ahmed M, Al Harbi Khalid, Qutob Rayan Abubakker, Almansour Mohammed

СтатьяПеревод в очереди

Аннотация

BACKGROUND

Systemic Lupus Erythematosus (SLE) is an autoimmune inflammatory condition affecting multiple systems. Cardiovascular morbidity is a significant concern, with around 25% of SLE patients experiencing cardiac complications.

OBJECTIVE

This study aims to determine the prevalence of cardiovascular morbidity in SLE patients in King Fahad Medical City (KFMC) in Riyadh, Saudi Arabia.

METHODOLOGY: This retrospective record-based research was conducted at KFMC from January 2015 to October 2023. A review of the medical files of all SLE patients was accomplished.

RESULTS

The vast majority of the patients (90.9%) were females. The mean age for the patients was 36.5 years. The most common comorbidities were lupus nephritis (34.6%), hypothyroidism (18.4%), and anti-phospholipid syndrome (9.2%). The most commonly used medications were hydroxychloroquine (81.8%), corticosteroids (prednisolone) (43.0%), and mycophenolate mofetil (27.9%). Around 45.2% (n= 176) of the patients with SLE developed cardiovascular complications. The most commonly reported cardiovascular diseases that developed after diagnosing patients with SLE were hypertension (22.4%), valvular heart diseases (13.2%), and dyslipidemia (9.2%). The study also found that anti-dsDNA antibodies can reduce the likelihood of developing hypertension by 40%. This research contributes to the medical literature on SLE and sets the stage for future research on personalized healthcare strategies for managing SLE and its complications.

CONCLUSION

This study highlights that a considerable proportion of SLE patients(~50%) develop cardiovascular complications, with hypertension, valvular heart diseases, and dyslipidemia being the most common. We also discovered that anti-double-stranded deoxyribonucleic acid antibodies (Anti-dsDNA) reduce the likelihood of developing hypertension.

Для цитирования: Alammari Yousef, Albednah Fahed A, Alharbi Khalid A, Alrashoudi Abdulrahman M, Alsharif Abdulaziz Y, Alkahtani Abdullah H, Alshehry Hasan Z, Alajaji Abdulrahman A, Alsaedi Ahmed M, Al Harbi Khalid, Qutob Rayan Abubakker, Almansour Mohammed. Cardiovascular Morbidity in Systemic Lupus Erythematosus: A Single-Center Retrospective Study.. Cureus. 2024. DOI: 10.7759/cureus.57842.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.